janssen, page-2

Thanks Wayne. Yes, it sure would be transformational.

You wrote;

Not only would it "create opportunities to further expand the relationship with Janssen" but it would also provide compelling validation for the technology.

Indeed it would.

In the Annual Report Phylogica highlighted this passage:

While the above Pharma alliances with Genentech, MedImmune and Pfizer have not been terminated by our partners, we believe that the likelihood of the candidates progressing into the partners’ preclinical programs is relatively low, given that the Phylomer approaches represent ‘backups’ of existing internal Pharma programs, which have not yet failed in development.

Even though current programs with the above mentioned Pharma progressing to clinic are relatively low, it doesn't mean they wouldn't be interested in the new endosomal escape technology.

and...

This approach has already been validated as part of the Janssen collaboration and opens up enormous opportunities to collaborate with other Pharma partners to enhance delivery of their existing drugs such antibodies, scaffolds and oligonucleotides (eg siRNA).

Still more scope with existing alliances...

Synthetic Phylomer peptide libraries:

The new technology has direct application to Phylogica’s existing alliances, include the design of ‘universal biosensor arrays’ (in collaboration with University of Queensland) and Phenotypic screens (in collaboration with Cambridge University).

The global market for biomarkers is predicted be worth $13 billion The market is expected to grow rapidly as the regulatory authorities such as the FDA are increasingly recognising the importance of biomarkers for drug development.

Regards,
Tony